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METHODS OF DELAYING DEVELOPMENT
OF CEA-ASSOCIATED TUMORS USING
ANTI-IDIOTYPE ANTIBODY 3H1

Changes of hapten carrier alloW T cell helper cells to
become active, making the overall immune response stron

CROSS-REFERENCE TO RELATED
APPLICATIONS

J. Cancer 53:707. Often the immunological status of a

ger. Thus, changing the carrier can also turn a tolerogenic

antigen into an effective antigen. McBridge et al. (1986) Br.

cancer patient is suppressed such that the patient is only able
to respond to certain T-dependent antigens and not to other
antigen forms. From these considerations, it Would make

This application is a continuation of US. patent applica
tion Ser. No. 10/162,396, noW abandoned, Which is a con

sense to introduce molecular changes into the tumor asso

tinuation of US. patent application Ser. No. 09/844,736,

ciated antigens before using them as vaccines. Unfortu
nately, this is impossible to accomplish for most tumor

noW abandoned, Which is a continuation of US. patent

antigens, because they are not Well de?ned and are very hard

application Ser. No. 08/838,692, now US. Pat. No. 6,235,
280, Which claims the bene?t of US. Provisional application
60/044,455, noW expired.
STATEMENT OF RIGHTS TO INVENTIONS
MADE UNDER FEDERALLY SPONSORED
RESEARCH
20

(Not Applicable)
FIELD OF THE INVENTION

This invention relates to uses of anti-idiotype antibodies.

25

More particularly, it relates to methods of treatment using

anti-idiotype antibody 3H1, in Which administration of 3H1
delays CEA-associated tumor development.
BACKGROUND OF THE INVENTION

to purify.
The netWork hypothesis of Lindemann ((1973) Ann.
Immunol. 124:171-184) and Jeme ((1974) Ann. Immunol.
125:373-389) offers an elegant approach to transform
epitope structures into idiotypic determinants expressed on
the surface of antibodies. According to the netWork concept,
immunization With a given tumor-associated antigen Will
generate production of antibodies against this tumor-asso
ciated antigen, termed Ab1; this Ab1 is then used to generate
a series of anti-idiotype antibodies against the Ab1 termed
Ab2. Some of these Ab2 molecules can effectively mimic
the three-dimensional structure of the tumor-associated anti

gen identi?ed by the Ab1. These particular anti-idiotypes
called Ab2[3 ?t into the paratopes of Ab1, and express the
internal image of the tumor-associated antigen. The Ab2[3
can induce speci?c immune responses similar to those

30

induced by the original tumor-associated antigen and can,
therefore, be used as surrogate tumor-associated antigens.
Immunization With Ab2[3 can lead to the generation of

In spite of extensive medical research and numerous
advances, cancer remains the second leading cause of death
in the United States. Colorectal cancer is the third most

anti-anti-idiotype antibodies (Ab3) that recogniZe the cor

responding original tumor associated antigen identi?ed by

common cancer and the second leading cause of cancer

Ab1. Because of this Ab1-like reactivity, the Ab3 is also
called Ab1' to indicate that it might differ in its other

deaths. While the traditional modes of therapy, such as

idiotopes from Ab1.

surgery, radiotherapy and chemotherapy, are Widely used
and are in many instances successfull, the still existing high

immunotherapy employing anti-idiotype antibodies. In this

death rate from cancers such as colorectal compels the need

35

A potentially promising approach to cancer treatment is
40

for alternative or additional modes of therapy.
Even if a patient responds to traditional modes of therapy,
there is often a signi?cant risk of recurrence of the disease.

This is especially true if the disease has spread When
diagnosed. Even after “successful” treatment, in Which a
remission is observed, a patient can have high risk of

stimulate the patient’s immune system against the tumor, via

45

only a fraction of antibodies raised against an Ab1 are

recurrence.

limited in their reactivity to the paratope of Ab1 (i.e., are
50

several reasons. It has been consistently difficult to obtain

are often chemically ill-de?ned and difficult to purify. In

55

the question of Whether a cancer patient can effectively
mount an immune response against his or her tumor. Tumor

nogenic anti-idiotypes elicit an immune response against the
tumor antigen and not against other antigens With less
speci?city. Moreover, since different cancers have Widely
varying molecular and clinical characteristics, it has been
suggested that anti-idiotype therapy should be evaluated on
a case by case basis, in terms of tumor origin and antigens

associated antigens (TAA) are often a part of “self” and
usually evoke a very poor immune response in a tumor

non-reactive against features shared With other potential
antibodies in the host). Second, anti-idiotype antibodies are
not necessarily immunogenic. Third, even if an anti-idiotype
elicits an immune response, only a fraction of these immu

large quantities or puri?ed tumor-associated antigens Which
addition, there remains the problem of immunobiological
response potential against tumor antigens, or in other Words,

the tumor-associated protein. WO 91/11465 describes meth
ods of stimulating an immune response in a human against
malignant cells or an infectious agent using primate anti

idiotype antibodies. HoWever, not all anti-idiotype antibod
ies can be used in therapeutic regimens against tumors. First,

recurrence, and can only “Watch and, Wait.” There are
presently no further courses of action to delay or prevent

One approach to cancer therapy has been immunotherapy.
HoWever, immunotherapy of human cancer using tumor
cells or tumor-derived vaccines has been disappointing for

form of therapy, an antibody mimicking an epitope of a
tumor -associated protein is administered in an effort to

60

expressed.

bearing host due to tolerance to the antigens, such as T

Anti-Id monoclonal antibodies structurally resembling

cell-mediated suppression. Moreover, cancer patients tend to

tumor-associated antigens have been used as antigen sub
stitutes in cancer patients. Herlyn et al. (1987) Proc. Natl.
Acad. Sci. USA. 84:8055-8059; Mittleman et al. (1992)
Proc. Natl. Acad. Sci. USA. 891466-470; Chatterjee et al.
(1993)Ann. NYAcad. Sci. 690:376-278. All ofthese studies
Were conducted With patients having advanced disease.

be immunosuppressed and only respond to certain T-depen
dent antigens.
Immunobiologists have learned that a poor antigen (in
terms of eliciting an immune response) can be turned into a

strong antigen by clanging the molecular environment.
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Based on the observed immune response in at least some of

vidual. In another aspect, the invention further includes
administration of 3H1 With an adjuvant.
In another aspect, methods are provided for treatment of

the patients, it has been proposed that the anti-Id provides a
partial analog of the tumor-associated antigen in an immu
nogenic context.

a CEA-associated tumor in an individual With a loW tumor

burden Which entail administering an effective amount of
3H1 to the individual.
In another aspect, methods are provided for treatment of

Carcinoembryonic antigen (CEA) is a 180,000-kiloDal
ton glycoprotein tumor-associated antigen present on endo

dermally-derived neoplasms of the gastrointestinal tract,
such as colorectal and pancreatic cancer, as Well as other

a CEA-associated tumor in an individual having a loW tumor

adenocarcinomas such as breast and lung cancers. A major

burden and having a level of circulating CEA less than about
50 ng/ml, Which entail administration of an effective amount

ity of colorectal, gastric, pancreatic as Well as breast and

of 3H1 to the individual.
In another aspect, 3H1 is used to treat a CEA-associated
tumor of colon or colorectal origin. These methods include
administration of an effective amount of 5-?uorouracil,
levamisole hydrochloride or leucovorin calcium, and an

non-small cell lung carcinomas are associated With CEA.
CEAis also found in the digestive organs of the human fetus.
Circulating CEA can be detected in the great majority of

patients With CEA-positive tumors. Speci?c monoclonal
antibodies have been raised against CEA and some have
been radiolabeled for diagnostic and clinical studies. Hansen
et al. (1993) Cancer 71:3478-3485; Karoki et al. (1992)

effective amount of 3H1 to an individual.

BRIEF DESCRIPTION OF THE DRAWINGS

Hibridoma 11:391-407; Goldenberg (1993) Am. J. Med.
94:297-312. As With most tumor-associated antigens Which
are seen as self-antigens by the immune system, cancer

patients are immunologically “tolerant” to CEA, likely
related to its oncofetal origin. This has rendered immuno
therapy based on CEA virtually impossible. Studies to date
on patients With CEA-positive tumors have not demon
strated the ability to generate immunity to CEA.
CEA nonetheless is an excellent tumor-associated antigen

20

assay of anti-CEA antibody; FIGS. 1(C) and (D) depict T
cell proliferative response (solid bar denotes CEA; open bar
25

for active immunotherapy With anti-idiotype antibody for
several reasons. CEA is typically present at high levels on
the tumor cell surface. CEA is also one of the most Well
characteriZed antigens, as its gene sequence is knoWn and its
three dimensional structures have been identi?ed. CEA is a

member of the immunoglobulin supergene family located on
chromosome 19 Which is thought to be involved in cell-cell
interactions.

denotes 3H1). N indicates PBS vaccinated mice.
FIG. 2 is a series of graphs depicting the increased
survival after tumor challenge in mice inoculated With 3H1.
Survival Was measured after six immuniZations With 3H1.

Circles denote challenge With MC38 (CEA negative) cells;
squares denote challenge With MC38cea (CEA positive)
30

cells. FIG. 2(A) shoWs percent survival of mice immuniZed
With 3H1-KLH. FIG. 2(B) shoWs percent survival of mice

immuniZed With isotype matched anti-idiotype antibody
11D10 conjugated to KLH. FIG. 2(C) shoWs percent sur
vival of mice immuniZed With PBS.

Inasmuch as some of the epitopes on CEA are shared by

normal tissues, immunization With intact CEA molecule

might trigger potentially harmful autoimmune reactions. An

FIGS. 1(A)-(D) are graphs depicting the generation of an
immune response in mice inoculated With 3H1. FIG. 1(A)
depicts an assay of anti-3H1 antibody; FIG. 1(B) depicts an
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immune reaction against a tumor associated epitope, on the

other hand, Would be desirable. A number of investigators

FIG. 3 is a graph depicting inhibition of binding of Ab1
(8019) to Ab2 (3H1) the presence of 6 high risk patients’
sera (after administration of 3H1). Squares With dots in the
center denote patient #1; solid diamonds denote patient #2;

have generated anti-idiotype antibodies in rats, mice,

solid squares With open center denote patient #3; open

baboons and humans that mimic CEA. See, e.g., Hinoda et
al. (1995) Tumor Biol. 16:48-55; Losman et al. (1994) Int. J.
Canoer 56:580-584; Irvine et al. (1993) Cancer Immunol.

diamonds denote patient #4; solid squares denote patient #5;
40

?uorouracil (5-FU) and levamisole concurrently With 3H1.
FIG. 4 is a bar graph depicting antibody dependent
cellular cytotoxicity (ADCC) in the sera of 6 high risk
patients receiving 3H1. The ?rst through sixth bars represent

Immunolher. 36:281-292. HoWever, given the siZe of CEA
(and likely numerous epitopes), and the fact that CEA is
expressed on some normal tissues, it Was not knoWn Whether

anti-idiotype antibodies Would be effective in eliciting an
anti-CEA response that effects anti-tumor immunity.

open squares denote patient #6. Patients #1 -3 Were receiving

45

patient numbers 1 through 6, respectively.
FIG. 5 is a bar graph depicting ADCC in the sera of 2 high

CEA-associated tumors, such as carcinomas of the gas
trointestinal tract, are often not curable by standard thera

risk patients receiving 3H1. In both halves of the graph,

pies. Even if a patient responds to traditional therapy, there

patient #1 (left side) or patient #2 (right side).

is often a signi?cant risk of recurrence. Thus, neW thera

peutic approaches for this disease are needed. The present
invention overcomes the de?ciencies in the prior art by
providing methods of treatment for CEA-associated tumors

effector cells from patient #1 Were used Ab3 Was from
50

residues.

using monoclonal anti-idiotype antibody (3H1) Which
escapes immune tolerance and induces an anti-CEA immune
response.

FIG. 6 depicts the cDNA sequence (SEQ ID NO:3; FIG.
6A) and the amino acid sequence (SEQ ID NO:4; FIG. 6B)
of the light chain variable region of 3H1 and adjoining

55

All references cited herein are incorporated by reference

FIG. 7 depicts the cDNA sequence (SEQ ID NO:5; FIG.
7A); and the amino acid sequence (SEQ ID NO:6; FIG. 7B)
of the heavy chain variable region of 3H1 and adjoining
residues.

in their entirety.

FIGS. 8(A) and (B) are graphs depicting detection of an
immune response to 3H1 in mice at varying dilutions of sera.

SUMMARY OF THE INVENTION
60

The present invention is directed to therapeutic uses of the

anti-idiotype antibody 3H1.

control plates coated With 3H1 but serum samples Were from
mice immuniZed 5 times With 1A7-KLH conjugate. Other
lines in the graph indicate different numbers of immuniZa

Accordingly, one aspect of the invention is methods of
delaying development of CEA-associated tumors an indi

vidual having a loW tumor burden, particularly high risk

FIG. 8(A) depicts an assay of anti-3H1 antibody; FIG. 8(B)
depicts an assay of anti-CEA (Ab1') antibody. In FIG. 8(A),
Ab2-C1 denotes control antibody 1A7; Ab2-C2 denotes

65

tions (3x; 5x; 6x; 7x) and pre-immune serum. In FIG. 8(B),

individuals. These methods include administration of an

absorbance Was measured before and after 3 (“3x”), 5

effective amount of anti-idiotype antibody 3H1 to the indi

(“5x”), and 7 (“7”) Weekly injections.

US 7,300,651 B2
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FIGS. 9(A)-(F) are tracings of How cytometric analysis of
Ab1' generated in mice by immunization With 3H1. FIGS.

Was minimal for all 12 patients. HoWever, all of these

9(A)-(C) show incubation of MC-38-cea cells (A, sera from
mice before and after six immunizations With 3H1-KLH

De?nitions

patients displayed normal disease progression.
As used herein, the terms “3H1,” “3H1 antibody” and
“3H1 monoclonal anti-idiotype antibody” are used inter
changeably to refer to an anti-idiotype antibody (Ab2) Which

conjugate; B, PBS and monoclonal anti-CEA antibody 8019;
C, sera from mice before and after six immunizations With

isotype-matched unrelated anti-idiotype antibody 1A7

contains an epitope that at least partially resembles a distinct

KLH. FIGS. 9(D)-(F) shoW incubation of MC-38 cells (D,
before and after six immunizations With 3H1-KLH conju
gate; E, PBS and 8019; F, before and after six immunizations

and speci?c epitope of the 180,000 M.W. carcinoembryonic

antigen (CEA) primarily expressed in high density by
human pancreatic and colonic tumor cells. The generation
and characterization of 3H1 is described in commonly
oWned patent application Ser. No. 08/579,940. Di?ferent
biological functions are associated With 3H1, including, but

With 1A7-KLH).
FIG. 10 is a bar graph depicting ADCC by serum from
mice immunized With 3H1. Diagonally hatched bar denotes
3H1 (1:5); open bar denotes 3H1 (1:10); cross hatched bar
denotes PBS (1:5); vertically hatched bar denotes PBS

not limited to, binding to Ab1 (8019) and/or Ab3 and an
ability to induce an immune response (humoral and/or

(1:10).

cellular) against CEA in mice, rabbits, monkeys, and
humans With advanced CEA-associated disease, particularly

DETAILED DESCRIPTION OF THE
INVENTION

We have discovered that administration of 3H1 increases

20

survival in mice having CEA-positive tumors and protects

CEA-associated tumors, as Well as humans With a history of
CEA-associated disease but no detectable disease.
A “CEA-associated tumor” is one that contains a CEA

antigen, especially expressed on the tumor cell surface.

mice from a tumor challenge. We have also found that

Methods of detecting CEA are knoWn in the art and
examples are described herein.

administration of the anti-idiotype antibody 3H1 in humans
Who have had CEA-associated tumors successfully treated

bene?cial or desired clinical results. For purposes of this

(i.e., no detectable metastasis or disease) elicits a CEA

As used herein, “treatment” is an approach for obtaining
25

speci?c immune response. Importantly, We have also dis
covered that administration of 3H1 to individuals having

are not limited to, one or more of the folloWing: alleviation

of symptoms, diminishment of extent of disease, stabilized

loW tumor burden Who are at high risk of recurrence of

CEA-associated tumors remain asymptomatic longer than
Would be statistically expected. In particular, one patient

(i.e., not Worsening) state of disease, preventing spread (i.e.,
metastasis) of disease, preventing occurrence or recurrence
30

With virtually a 100% risk of recurrence Within six months

total). Also encompassed by “treatment” is a reduction of

ing 3H1. We believe that administration of 3H1 can reduce
the risk of CEA-associated tumor occurrence, particularly in

3H1 is a murine monoclonal anti-idiotype (Id) antibody
(Ab2) Which induces a speci?c immune response against a

of disease, delay or sloWing of disease progression, amelio
ration of the disease state, and remission (Whether partial or

remained asymptomatic for over tWenty months after receiv

high risk individuals in the adjuvant setting.

invention, bene?cial or desired clinical results include, but

35

pathological consequences of a CEA-associated tumor(s).
As used herein, “delaying” development of a CEA-asso
ciated tumor(s) means to defer, hinder, sloW, retard, stabi

distinct and speci?c epitope of carcinoembryonic antigen

lize, and/or postpone development of the disease. This delay
can be of varying lengths of time, depending on the history
of the disease and/or individual being treated. As is evident

(CEA), a tumor-associated antigen. This epitope is unique to

to one skilled in the art, a suf?cient or signi?cant delay can,

CEA and is not present on other CEA-related loWer molecu
lar Weight members of this family Which are also found on

40

normal tissues. The antigenic determinant as de?ned by the
monoclonal antibody 8019 (Ab1) against Which 3H1 Was

in effect, encompass prevention, in that the individual does
not develop the disease. A method that “delays” develop
ment of CEA-associated tumor(s) is a method that reduces

probability of disease development in a given time frame

raised is absent on normal adult tissues as evidenced by

and/or reduces extent of the disease in a given time frame,

immunoperoxidase staining and hematopoietic analysis. The

When compared to not using the method. Such comparisons

generation and characterization of 3H1 has been described

45

are typically based on clinical studies, using a statistically

in commonly oWned US. Pat. No. 5,977,315, as Well as the

signi?cant number of subjects.

DNA sequences encoding the variable regions of 3H1 (light
and heavy chains). A hybridoma that produces 3H1 has been
deposited With the American Type Culture Collection
(ATCC), 12301 ParklaWn Drive, Rockville, Md., USA.
20852 on Dec. 15, 1995, under the provisions of the Budap
est Treaty for the International Recognition of the Deposit of

“Development” of CEA-associated tumor(s) means pro
gression of the tumor(s). Tumor development can be detect
able using standard clinical techniques as described herein.
HoWever, development also refers to disease progression
that may be undetectable. For purposes of this invention,
progression refers to the biological course of the disease
state, in this case (i.e., CEA-associated tumors) cell division
and/or metastasis of the CEA-associated tumor. “Develop

Microorganisms for the Purposes of Patent Procedure. It Was
accorded Accession Number HB12003.
In a previous Phase I clinical trial, 12 colorectal cancer

patients having advanced CEA-associated disease (Who had
failed all previous therapy and still had high tumor burden)

50
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Were administered 3H1. Bhattacharya-Chatterjee et al.

(1994) XVIInZernaZ’l Cancer Congress pp. 495-498. Nine of

the 12 patients developed high titers of speci?c anti-anti-Id
(Ab3) antibodies that Were capable of inhibiting binding of

60

Ab1 to Ab2 or CEA. All nine of these patients also generated

ment” includes occurrence, recurrence, and onset. As used
herein “onset” or “occurrence” of CEA-associated disease
includes initial onset and and/or recurrence.
As used herein, “loW tumor burden” means that an
individual does not have advanced CEA-associated

tumor(s). “Advanced” CEA-associated tumor(s) means that
there is detectable metastasis, that is, detectable tumor
masses at sites other than the primary site of the tumor.

speci?c anti-CEA antibodies Which reacted With puri?ed

Tumor masses are preferably detected by imaging tech

CEA and shoWed the identical immunostaining patterns as
Ab1 on autologous and allogeneic colonic tumors. Further
more, 7 of the 12 patients demonstrated Id-speci?c T cell
proliferative responses. Four of these seven patients also
shoWed T cell proliferation in the presence of CEA. Toxicity

niques knoWn in the art such as X-ray, CT scan, or MRI.

“Advanced” disease does not include lymph node involve
65

ment. As the term indicates, “loW tumor burden” indicates a

lesser extent of disease than the maximum, or end-stage
levels that have been described for CEA-associated tumors.
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It is understood that “loW tumor burden” also includes no

An “individual” is a vertebrate, preferably mammal, more
preferably human. Mammals include, but are not limited to,

detectable tumor. Examples of loW tumor burden categories
are provided beloW.

farm animals, sport animals, and pets.

As used herein, a “high risk” individual is an individual

Who is at major risk of development of CEA-associated

EMBODIMENTS OF THE INVENTION

tumors. A “high risk” individual may or may not have
detectable disease, and may or may not have displayed
detectable disease prior to the treatment methods described
herein. “High risk” denotes that an individual has one or
more so-called risk factors, Which are measurable param

delaying development of a CEA-associated tumor(s) in

In one embodiment, the invention provides methods
Which an effective amount of 3H1 is administered to an

individual having a loW tumor burden. Examples of CEA
associated tumors include, but are not limited to, carcinomas

eters that correlate With development of CEA-associated

of the gastrointestinal tract (including colorectal cancer),
other adenocarcinomas such as breast, lung (non small cell)
cancer, biliary (including biliary tree) cancer and gyneco

tumors. An individual having one or more of these risk

factors has a higher probability of developing CEA-associ
ated tumors than an individual Without these risk factor(s).
These risk factors include, but are not limited to, age, sex,

race, diet, history of previous disease, presence of precursor

logical cancer. Methods of detecting CEA-associated tumors
are knoWn in the art, including standard immunoassay
techniques. As an example, CEA-associated tumors can be

disease, genetic (i.e., hereditary) considerations, and envi
ronmental exposure. Examples (i.e., categories) of high-risk

detected by standard immunohistologic examination of
affected tissue, using, for example, 8019 as the primary

groups are discussed beloW.

Depending on the basis and context of assessment of high
risk, the time frame Within Which probability of disease or
tumor development, progression, and/or onset Would more
likely than not occur Would vary. For instance, With breast,

colorectal, and/or adenocarcinoma high risk patients in the
adjuvant setting, the risk of occurrence is typically measured

20

antibody in an indirect immuno?uorescence assay.
In one embodiment, the invention encompasses adminis
tration of 3H1 to a high risk individual having a loW tumor

burden. As discussed above, a high risk individual displays
one or more risk factors that correlate With CEA-associated

tumor development. High (i.e., increased) risk may be
25

indicated, for example, on the basis of an individual’s

genotype (for example, familial polyps), increased expres

Within one to tWo years. For patients Who display precursor
disease, the risk of occurrence can be measured in a longer
time frame. For an individual Who is considered high risk

sion of tumor-associated genes or decreased expression of
tumor suppressor genes, presence of precursor disease (such
as polyps), a family history of CEA-associated cancer, a

due to, for example, genetic or hereditary considerations, the

risk of occurrence can be measured in an even longer time 30 history of exposure to an environmental substance or form

of radiation Which is knoWn or suspected of being carcino

frame, including the expected lifetime of the individual.

genic or teratogenic (particularly suspected of causing CEA

An individual With “loW risk” is one Who is not consid

associated tumors), exposure to a potentially carcinogenic

ered “high risk”.
“Adjuvant setting” refers to a clinical setting in Which an
individual has had a history of CEA-associated disease,
particularly CEA-associated tumors, and has been respon
sive to therapy. The prior therapy can have included, but is

35

of having a CEA positive tumor based on a positive test for

Because all risk factors for developing CEA-associated
tumors are not knoWn, and the interplay among these factors
40

their history of CEA-associated disease, these individuals

clinical features in common, and that individuals not falling
clearly in the categories described above can nonetheless be
considered suitable candidates for administration of 3H1. A

subsequent mode of treatment. The degree of risk (i.e.,
Whether an individual in the adjuvant setting is considered

“high risk” or “loW risk”) depends upon several factors,

skilled clinician can make an empirical determination
Whether an individual is suitable for 3H1 treatment. For

most usually the extent of disease When ?rst treated.

As used herein, “adjuvant setting” is distinguished from

example, an individual With a familial (i.e., genetic) history

an “adjuvant”, Which refers to a chemical or biological agent

an agent (such as an antibody, polynucleotide or polypep

(in terms of overall risk) are not fully understood, it is clear
to one skilled in the art that individuals suitable for admin
istration of 3H1 for purposes of this invention can have

are considered at risk of development of the disease. Treat
ment or administration in the “adjuvant setting” refers to a

in a pharmaceutical preparation given in combination With

groWth. Also included as high risk are individuals suspected

anti-CEA immunological reactivity.

not limited to, surgical resection, radiotherapy, and chemo
therapy. As a result of this prior therapy, these individuals
have no clinically measurable tumor. HoWever, because of

pathogen such as a retrovirus, or a history of other types of
cancer or other types of abnormal or unregulated tissue

50

of colorectal cancer could be considered “high risk”, even
though no previous disease in this individual has been
observed. In this context, administration of 3H1 to such an

tide) to enhance its immunogenicity. Examples of adjuvants

individual could result in delay of occurrence of disease, to
the extent that the individual does not develop the disease
Within his or her lifetime (or develops it later than Would
have been expected). Another example is an individual Who

are described herein.

A “neo-adjuvant setting” refers to the period after diag
nosis but before initiation of treatment modalities other than
administration of 3H1. For example, if an individual is
diagnosed as having a CEA-associated tumor, such as col

orectal, for Which surgery is indicated, administration of

is being treated using traditional modes of therapy, and Who
is shoWing clinical responsiveness to the therapy (i.e., remis
sion). Such an individual may be adjudged as “high risk”,

3H1 in a neo-adjuvant setting means that administration of

even though the initial course of therapy is not yet com

3H1 commences before surgery.
pleted, due to projection of clinical progress by the clinician
An “effective amount” is an amount suf?cient to effect 60 and can be a suitable candidate for receiving 3H1 before
completion of the initial therapy. The clinician, as one
bene?cial or desired clinical results. An effective amount can
skilled in the art, has discretion to determine Whether
be administered in one or more administrations. For pur
treatment using 3H1 may be indicated.
poses of this invention, an effective amount of 3H1 is an

amount of 3H1 that is suf?cient to ameliorate, stabiliZe, or

delay the development of the CEA-associated disease state,
particularly CEA-associated tumors. Detection and mea
surement of these indicators of ef?cacy are discussed beloW.

65

It is also evident that administration of 3H1 may be
indicated even if an individual is not adjudged to be high risk

(i.e., is “loW risk”) according to concurrent clinical risk
assessment criteria. For instance, an individual Who has been

US 7,300,651 B2
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successfully treated and is not considered high risk (due, for
example, to the lack of detectable invasive disease at the
time of diagnosis) may nonetheless be a candidate for
receiving 3H1 as a precautionary measure, especially con
sidering the lack of contraindications and lack of undesirable
side effects so far observed from 3H1. Thus, the risk of
disease progression may be loWered even further by admin
istration of 3H1. As another example, an individual may
believe that he or she is at risk of disease development, and
may decide that receiving 3H1 Would reduce this risk. Also
suitable are individuals With supernormal levels of circulat

The invention also includes methods of treatment using

3H1 for individuals having residual disease, particularly
minimal residual disease. “Residual” disease is any CEA

associated disease, particularly CEA-associated tumor(s)
5

“residual disease” refers to the likely presence of disease
that can develop into detectable disease, and refers to a

clinical prognosis and/or assumption made in an adjuvant
setting. Depending on the type of CEA-associated tumor
and, for example, the extent of disease upon diagnosis, an
individual can be adjudged to have residual disease, even
though no detectable disease is present. For example, an
individual With resectable lung adenocarcinoma has residual
disease after surgery (i.e., resection), even if an apparent
complete remission has occurred. Similarly, an individual

ing CEA and/or supernormal levels of CEA expression. The
circulating level of CEA can be determined by standard

immunoassay (ELISA) techniques Which are commercially
available (Hybritech). Levels of CEA expression can be

With colorectal cancer can have residual disease after che

determined by, for example, immunohistologic examination

motherapy. Alternatively, an individual Who is currently

of affected tissue, using, for example, 8019 as the primary
antibody in an indirect immuno?uoresce assay.
As used herein, “supernormal” levels of CEA are greater
than about 3 ng/ml. As is evident to one of skill in the art,
the levels of circulating CEA can vary among laboratories

(and depending upon the method and/or commercial kit
used). Thus, supernormal levels of CEA can be greater than
about 1 ng/ml to greater than about 5 ng/ml.
In another embodiment of the present invention, 3H1 is
administered to a high risk individual in the adjuvant setting.
Factors typical as indicating individuals of high risk in the
adjuvant setting are invasion by the tumor into neighboring

tissues (i.e., extensive disease), and/or lymph node involve
ment. Examples of high risk individuals in the adjuvant
setting include, but are not limited to, (a) patients With Stage
II or Stage IIIA adenocarcinoma of the lung With positive
lymph nodes Who have had their tumor resected (these
patients have a 60-80% relapse rate in the ?rst 2 years); (b)
patients With breast cancer Who have positive lymph nodes
in preferably at least 5, more preferably at least 10 (70-80%

20

CEA-associated disease. “Reducing risk of occurrence”
25

3H1 than those individuals (having the same risk of occur

rence) Who do not. An individual “at risk” for developing
CEA-associated disease can be high risk or loW risk,
30

The invention also encompasses methods of treatment of

35
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knoWn in the art and some are described herein (see, e.g.,

Example 4).
45

invention, an individual in a neo-adjuvant setting has a loW
tumor burden.

Another example of an individual suitable for 3H1
therapy as described in this invention is an individual With

or complete remission as adjudged by a clinical practitioner.

50

3H1. We believe that 5-FU and levamisole or leucovorin
may act synergistically With 3H1 to enhance the immune

currently knoWn in the art, and for purposes of this inven
tion, they are administered according to accepted clinical
protocols (described in more detail beloW).
55

For all of the above-described embodiments of the present
invention, 3H1 can be prepared, administered, and moni
tored as described in the folloWing sections.

“LoW” tumor burden can also arise by a reduction of tumor

Preparation and Administration of Anti-idiotype Antibody
60

3H1
All embodiments of this invention entail administration of
an effective amount of 3H1.

levels are usually less than or equal to about 50 ng/ml,
preferably less than or equal to about 10 ng/ml, more
preferably less than or equal to about 5 ng/ml, even more
preferably less than or equal to about 3 ng/ml. An individual
With a loW tumor burden can be further classi?ed as “high

In another embodiment, the invention provides methods
of treating a CEA-associated tumor, particularly adenocar
cinoma, particularly adenocarcinoma of the colon and/or
rectum, Which include administration of ?uorouracil (5-FU)
With levamisole hydrochloride or leucovorin calcium, and
response. 5-FU With levamisole or leucovorin are treatments

burden of advanced disease such that the extent of disease is
no longer considered advanced. Other examples of loW
tumor burden include disease contained to limited lymph

node involvement. For these individuals, circulating CEA

burden and Who has a circulating level of CEA less than
about 50 ng/ml. These methods entail administration of an
effective amount of 3H1 to the individual. Preferably, the
individual has a circulating level of CEA less than about 30
ng/ml, more preferably less than about 25 ng/ml, still more
preferably less than about 20 ng/ml, even more preferably
less than about 15 ng/ml, even more preferably less than
about 10 ng/ml, even more preferably less than about 5

ng/ml. Methods of measuring levels of circulating CEA are

In another embodiment, 3H1 is administered in a neo

effective amount of 3H1. As de?ned above, a “loW” tumor
burden means that the disease is not considered advanced.
For example, a loW tumor burden can be disease in partial

depending on the clinical and genetic history and status of
the individual.
a CEA-associated tumor in an individual having a loW tumor

not limited to, pancreatic, gastric and biliary (including
biliary tree) cancers.

loW tumor burden. Thus, the present invention encompasses
methods of treating CEA-associated tumors in an individual
having a loW tumor burden comprising administering an

means that the risk of occurrence and/or reoccurrence of

CEA-associated disease is loWer in individuals receiving

positive lymph nodes); and (c) patients With colon cancer
With at least 4 positive lymph nodes (70-80% relapse rate in

adjuvant setting. It is understood that, for purposes of this

undergoing therapy for a CEA-associated tumor also has
“residual” disease. It is understood that, as used herein,
“residual” disease does not include advanced disease.
The invention also encompasses methods of reducing risk
of occurrence of CEA-associated disease, particularly CEA
associated tumors. In these methods, an effective amount of
3H1 is administered to an individual at risk for developing

relapse rate in the ?rst 2 years for those With at least 10

the ?rst 2 years). Another example of a high risk individual
in the adjuvant setting is an individual having a gastric
CEA-associated tumor that has been resected, including, but

remaining after therapy but Which is undetectable. Thus,

3H1 can be obtained several Ways. 3H1 can be produced
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from the hybridoma ATCC No. HB12003 described herein.
Methods of antibody isolation are Well knoWn in the art. See,
for example, HarloW and Lane (1988) Antibodies: A Labo

risk” or “loW risk,” depending on the individual’s clinical

ralory Manual, Cold Spring Harbor Laboratory, NeW York,

history.

and Sambrook et al. (1989) Molecular Cloning: A Labora

